Literature DB >> 27198162

Use of antipsychotics and risk of myocardial infarction: a systematic review and meta-analysis.

Zheng-He Yu1, Hai-Yin Jiang2, Li Shao2, Yuan-Yue Zhou3,4, Hai-Yan Shi2, Bing Ruan2.   

Abstract

AIM: There is emerging concern that antipsychotics may be associated with an increased risk of myocardial infarction (MI). A previous review identified five observational studies that did not provide an accurate estimate of the association between antipsychotic drug use and MI risk. More recent studies have produced variable results.
METHODS: We performed a systematic review and meta-analysis of observational studies to determine whether antipsychotic use affects the risk for MI. Our analysis included all observational studies that compared MI incidence among patients receiving antipsychotics vs. no treatment.
RESULTS: Nine observational studies were included in the analysis. The odds for developing MI were 1.88-fold higher (odds ratio (OR) 1.88, 95% confidence interval (CI) 1.39, 2.54) in antipsychotic users compared with individuals who had not taken antipsychotics. Subgroup analyses found an OR of 2.48 (95% CI 1.66, 3.69) among patients with schizophrenia and an OR of 2.64 (95% CI 2.48, 2.81) among short term (<30 days) antipsychotic users.
CONCLUSION: The findings of this meta-analysis support an increased risk of MI in antipsychotic drug users. The present systematic review expands previous knowledge by demonstrating an increased and more pronounced risk in short term users.
© 2016 The British Pharmacological Society.

Entities:  

Keywords:  antipsychotic agents; coronary disease; myocardial infarction

Mesh:

Substances:

Year:  2016        PMID: 27198162      PMCID: PMC5338104          DOI: 10.1111/bcp.12985

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  38 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Antipsychotics and risk of first-time hospitalization for myocardial infarction: a population-based case-control study.

Authors:  S Nakagawa; L Pedersen; M L Olsen; P B Mortensen; H T Sørensen; S P Johnsen
Journal:  J Intern Med       Date:  2006-11       Impact factor: 8.989

3.  Use of psychotropic drugs and risk of myocardial infarction: a case-control study in Finnish farmers.

Authors:  J Penttinen; P Valonen
Journal:  Int J Epidemiol       Date:  1996-08       Impact factor: 7.196

4.  Management of psychosis and schizophrenia in adults: summary of updated NICE guidance.

Authors:  Elizabeth Kuipers; Amina Yesufu-Udechuku; Clare Taylor; Tim Kendall
Journal:  BMJ       Date:  2014-02-12

5.  Antidepressant use and risk of coronary heart disease: meta-analysis of observational studies.

Authors:  Seung-Won Oh; Joonseok Kim; Seung-Kwon Myung; Seung-Sik Hwang; Dae-Hyun Yoon
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

Review 6.  Medical comorbidity in schizophrenia.

Authors:  D V Jeste; J A Gladsjo; L A Lindamer; J P Lacro
Journal:  Schizophr Bull       Date:  1996       Impact factor: 9.306

7.  D3 dopamine receptor regulation of ETB receptors in renal proximal tubule cells from WKY and SHRs.

Authors:  Changqing Yu; Zhiwei Yang; Hongmei Ren; Yie Zhang; Yu Han; Duofen He; Quansheng Lu; Xiaoyan Wang; Xukai Wang; Chengming Yang; Laureano D Asico; Ulrich Hopfer; Gilbert M Eisner; Pedro A Jose; Chunyu Zeng
Journal:  Am J Hypertens       Date:  2009-04-23       Impact factor: 2.689

Review 8.  Antipsychotics for delirium.

Authors:  E Lonergan; A M Britton; J Luxenberg; T Wyller
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

9.  Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund.

Authors:  S Weinbrenner; H-J Assion; T Stargardt; R Busse; G Juckel; C A Gericke
Journal:  Pharmacopsychiatry       Date:  2009-03-23       Impact factor: 5.788

Review 10.  The association between antipsychotic agents and the risk of myocardial infarction: a systematic review.

Authors:  Ruth Brauer; Ian Douglas; Liam Smeeth
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

View more
  10 in total

1.  Acute coronary syndromes: Use of antipsychotic drugs linked with risk of MI.

Authors:  Karina Huynh
Journal:  Nat Rev Cardiol       Date:  2016-06-03       Impact factor: 32.419

Review 2.  Use of antipsychotics and risk of myocardial infarction: a systematic review and meta-analysis.

Authors:  Zheng-He Yu; Hai-Yin Jiang; Li Shao; Yuan-Yue Zhou; Hai-Yan Shi; Bing Ruan
Journal:  Br J Clin Pharmacol       Date:  2016-05-23       Impact factor: 4.335

3.  Antipsychotic combinations in schizophrenia.

Authors:  C Gastaldon; D Papola; G Ostuzzi
Journal:  Epidemiol Psychiatr Sci       Date:  2017-06-05       Impact factor: 6.892

4.  Antipsychotic drug exposure and risk of myocardial infarction.

Authors:  C Barbui; C Gastaldon; D Papola; G Ostuzzi
Journal:  Epidemiol Psychiatr Sci       Date:  2016-11-22       Impact factor: 6.892

5.  Acute sleep interventions as an avenue for treatment of trauma-associated disorders.

Authors:  Kevin M Swift; Connie L Thomas; Thomas J Balkin; Emily G Lowery-Gionta; Liana M Matson
Journal:  J Clin Sleep Med       Date:  2022-09-01       Impact factor: 4.324

Review 6.  The intriguing relationship between coronary heart disease and mental disorders.

Authors:  Marc De Hert; Johan Detraux; Davy Vancampfort
Journal:  Dialogues Clin Neurosci       Date:  2018-03       Impact factor: 5.986

7.  Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis.

Authors:  Sanja Zivkovic; Chan Hee Koh; Nandita Kaza; Caroline A Jackson
Journal:  BMC Psychiatry       Date:  2019-06-20       Impact factor: 3.630

Review 8.  Neurological Disorders and Risk of Arrhythmia.

Authors:  Joyce Bernardi; Kelly A Aromolaran; Ademuyiwa S Aromolaran
Journal:  Int J Mol Sci       Date:  2020-12-27       Impact factor: 5.923

9.  Drug classification for patients with comorbidities.

Authors:  Farid Belialov
Journal:  J Pharm Policy Pract       Date:  2022-09-22

Review 10.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.